We're doing a major overhaul of our CPOE drug alerts and I'm looking for input from other pharmacy informaticists. Currently we have way too many alerts firing — the classic problem — and our override
We're doing a major overhaul of our CPOE drug alerts and I'm looking for input from other pharmacy informaticists. Currently we have way too many alerts firing — the classic problem — and our override rate tells us clinicians aren't reading them anymore. Our plan is to create a tiered approach: 1. Hard stops for truly dangerous interactions (contraindicated combos) 2. Interruptive alerts for significant clinical concerns 3. Passive/informational for nice-to-know items But the devil is in the details. How are other orgs deciding what goes in each tier? Are you using a specific evidence source (Clinical Pharmacology, Lexicomp, First Databank) as your baseline? And how do you handle the political side — the physicians who want fewer alerts vs. the risk managers who want more?
Sign in to join the discussion
Sign in